To view enhanced digital features for this article go to https://doi.org/10.6084/m9.figshare.7707836.
A water-soluble Cremophor EL-free formulation of paclitaxel, in which retinoic acid derivates solubilize paclitaxel by forming micelles (paclitaxel micellar), was studied for the first time in man to establish the maximum tolerated dose (MTD) and to characterize the pharmacokinetics (PK).
This was an open-label, one-arm, dose-escalating study in patients with advanced solid malignant tumours, for which no standard therapy was available or had failed. Paclitaxel micellar was given as 1-h intravenous infusion every 21 days for 3 cycles, mainly without premedication. Plasma samples were collected during 24 h at the first cycle and paclitaxel concentrations were assayed by high-performance liquid chromatography. PK was evaluated using a two-compartment model.
Thirty-four patients received paclitaxel micellar at doses ranging between 90 and 275 mg/m2. MTD was established as 250 mg/m2. Fatigue and neuropathy were the most frequent dose-limiting toxicities. No hypersensitivity reactions were observed. PK of paclitaxel was evaluated in 25 data sets. Paclitaxel micellar had a rapid initial distribution phase, mean half-life 0.55 h, estimated to be completed 3 h after dosing and a mean terminal half-life of 8.8 h. Mean clearance was 13.4 L/h/m2 with fivefold interindividual variability. The residual areas after 10 h and 24 h were 15.7 ± 8.6% and 5.7 ± 3.9% of the area under the plasma concentration–time curve to infinite time (AUCinf), respectively.
No new side effects unknown for paclitaxel were observed. Maximum plasma concentration (Cmax) and AUCinf showed a tendency to increase linearly with dose within the 150–275 mg/m2 dose range. The possibility to administer paclitaxel micellar without steroid premedication makes it an attractive candidate for further studies in combination with immunotherapy.
EudraCT no: 2004-001821-54.
Oasmia Pharmaceutical AB.
Konno T, Watanabe J, Ishihara K. Enhanced solubility of paclitaxel using water-soluble and biocompatible 2-methacryloyloxyethyl phosphorylcholine polymers. J Biomed Mater Res Part A. 2003;65(2):209–14. CrossRef
FDA, US Label. Taxol ® (paclitaxel) injection (Patient Information Included). Bristol-Myers Squibb Company. 2011. Reference ID:2939751. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020262s049lbl.pdf. Accessed 8 Oct 2018.
Rajappa S, Joshi A, Doval DC, Batra U, Rajendranath R. Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Int J Nanomed. 2018;10:3757–69.
European Medicines Agency. Assessment report for Apealea. https://www.ema.europa.eu/documents/assessment-report/apealea-epar-public-assessment-report_en.pdf. Accessed 2 Feb 2019.
Sparreboom A, de Bruijn P, Nooter K, Loos WJ, Stoter G, Verweij J. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;705(1):159–64. CrossRefPubMed
FDA, US Label. Highlights of prescribing information. Abraxane ® for injectable suspension (paclitaxel protein-bound particles for injectable suspension). Celgene. 2018. Reference ID: 4307748. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021660s045lbl.pdf. Accessed 8 Oct 2018.
European Medicines Agency. Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev 1/Corr**. 2010;1–27.
Rowland M, Tozer TN. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 3rd ed. Philadelphia: Wolters Kluwer Health/Lippincott William & Wilkins; 1995. pp. 164–165.
Brouwer E, Verweij J, De Bruijn P, et al. Measurement of fraction unbound paclitaxel in human plasma. Drug Metab Dispos. 2000;28(10):1141–5. PubMed
Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticl formulation of paclitaxel. Clin Cancer Res. 2002;8(5):1038–44. PubMed
- Maximum Tolerated Dose and Pharmacokinetics of Paclitaxel Micellar in Patients with Recurrent Malignant Solid Tumours: A Dose-Escalation Study
- Springer Healthcare
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II